Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing
AbstractAs recognised by the National Institutes of Health (NIH) Precision Medicine Initiative (PMI), microarray technology currently provides a rapid, inexpensive means of identifying large numbers of known genomic variants or gene transcripts in experimental and clinical settings. However new generation sequencing techniques are now being introduced in many clinical genetic contexts, particularly where novel mutations are involved. While these methods can be valuable for screening a restricted set of genes for known or novel mutations, implementation of whole genome sequencing in clinical practice continues to present challenges. Even very accurate high-throughput methods with small error rates can generate large numbers of false negative or false positive errors due to the high numbers of simultaneous readings. Additional validation is likely to be required for safe use of any such methods in clinical settings. Custom-designed arrays can offer advantages for screening for common, known mutations and, in this context, may currently be better suited for accredited, quality-controlled clinical genetic screening services, as illustrated by their successful application in several large-scale pre-emptive pharmacogenomics programs now underway. Excessive, inappropriate use of next-generation sequencing may waste scarce research funds and other resources. Microarrays presently remain the technology of choice in applications that require fast, cost-effective genome-wide screening of variants of known importance, particularly for large sample sizes. This commentary considers some of the applications where microarrays continue to offer advantages over next-generation sequencing technologies. View Full-Text
Share & Cite This Article
Shahandeh, A.; Johnstone, D.M.; Atkins, J.R.; Sontag, J.-M.; Heidari, M.; Daneshi, N.; Freeman-Acquah, E.; Milward, E.A. Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing. Microarrays 2016, 5, 12.
Shahandeh A, Johnstone DM, Atkins JR, Sontag J-M, Heidari M, Daneshi N, Freeman-Acquah E, Milward EA. Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing. Microarrays. 2016; 5(2):12.Chicago/Turabian Style
Shahandeh, Al; Johnstone, Daniel M.; Atkins, Joshua R.; Sontag, Jean-Marie; Heidari, Moones; Daneshi, Nilofar; Freeman-Acquah, Elvis; Milward, Elizabeth A. 2016. "Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing." Microarrays 5, no. 2: 12.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.